FY2025 · ended Dec 31, 2025 · Revenue $336,108, -45.5% YoY · Filed Mar 26, 2026
Provectus Biopharmaceuticals, Inc. (PVCT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $336,108 and a net loss of $5.4 million. As of Jun 30, 2026 it held $1.2 million in cash and investments and $103,900 in total debt.
Revenue
$336,108
-45.5% vs prior year
Net income
$-5.43M
-14.8% vs prior year
Operating cash flow (TTM)
$-2.43M
+21.6% vs year-ago TTM
Free cash flow
$-9.90M
+12.2% vs prior year
EPS
$-0.01
+0.0% vs prior year
Dividend per share
None
Shares outstanding
420.28M
+0.0% vs prior year
Net cash
$1.05M
as of Jun 30, 2026
Operating margin
-1575.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PVCT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Knoxville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 315545
- Former names
- PROVECTUS PHARMACEUTICALS INC (until Dec 18, 2013); PROVECTUS PHARMACEUTICAL INC (until May 15, 2002); ZAMAGE DIGITAL IMAGING INC (until Apr 1, 2002); SPM GROUP INC (until Nov 14, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — |
| Operating income | -$5.3M | -$4.5M | -$2.9M | -$3.4M | -$4.7M |
| Net income | -$5.4M | -$4.7M | -$3.1M | -$3.6M | -$5.5M |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | — | — |
| Operating cash flow | -$3.3M | -$3.3M | -$2.6M | -$3.0M | -$1.0M |
| Total assets | $697,502 | $1.0M | $1.4M | $2.0M | $3.5M |
| Total liabilities | $7.0M | $7.0M | $9.0M | $8.3M | $7.7M |
| Stockholders' equity | -$6.3M | -$6.0M | -$7.6M | -$6.2M | -$4.2M |
| Cash and investments | $251,291 | $307,442 | $76,576 | $21,605 | $682,984 |
| Total debt | $127,304 | $25,299 | $73,377 | $117,798 | $45,617 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 1000 Provectus Biopharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.